DIAGENS-B (02526.HK): iMedLoop Upgrade Launched Globally with API
NewTimeSpace News: On 19 November 2026, Hangzhou Diagens Biotechnology Co., Ltd. (stock code: 02526) announced that the upgraded version of iMedLoop, the Group's medical imaging model development, research and analysis platform, was officially launched at 9:00 a.m. Eastern Standard Time on 18 November 2026 (www.imedloop.com), with API subscriptions opened worldwide at the same time.
The upgrade integrates the Group's sixth-generation medical imaging foundation model, iMedImage 6.0 (iMed-6.0), and extends image analysis capabilities to general users. Users may use specialised models provided by the platform, or train, evaluate and deploy customised specialised models without programming; professional users can access the model's capabilities in their own research systems through API subscriptions.
The Group has accumulated a medical imaging dataset of over 1.1 billion images covering 19 imaging modalities, on which iMed-6.0 was trained, giving it capabilities including three-dimensional anatomical localisation, lesion measurement and dynamic image analysis. The Company said online platform services and API subscriptions complement existing institutional model licensing and localised delivery, helping expand its customer base and revenue sources.
The announcement also noted that personal image interpretation is for health information and educational reference only, that clinical diagnosis should be made by qualified medical professionals, that model functions pending regulatory approval are for research verification and teaching only, and that the launch and commercialisation of the platform remain uncertain.
- DIAGENS-B (02526.HK): iMed-6.0 Models Lead Benchmarks, Thoth Tops Overall Score
- DIAGENS-B (02526.HK): Three-Year Pact with Yongjiang Lab on Imaging AI
- HK Stock Connect Insight | DIAGENS-B (02526.HK): 778,962 options and RSUs granted, southbound holding ratio rises to 0.52%
- DIAGENS-B (02526.HK): Signs Three-Year Cooperation Framework Agreement with Anzhen'er on Provincial Medical Imaging AI Platform
- DIAGENS-B(02526.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 55.88 million, loss widened by 4070.37% YoY